Embecta Corp.

EMBC · NasdaqGS · Stock · Healthcare
$6.52
+5.50% today
Delayed price,

What Embecta does

Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. It primarily sells its products to wholesalers and distributors. The company was formerly known as Berra Newco, Inc. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.

Key facts

Sector
Healthcare
Industry
Medical Instruments & Supplies
Market cap
$369.4M
P/E (ttm)
4.5
Forward P/E
3.7
Dividend yield
0.64%
Beta
0.83
Profit margin
8.6%
Employees
1,850
Headquarters
Parsippany, NJ, United States
Exchange
NasdaqGS

Performance

1 Month
+23.3%
3 Months
+100.6%
6 Months
-33.3%
1 Year
-51.9%
5 Years
-78.6%
$2.7752-week range$14.91
Biggest setback — last 12 months
-78.7%
17 Nov 2025 → 8 Jun 2026
Fell from $14.57 to $3.10 — its sharpest sustained decline this year.
Biggest run-up — last 12 months
+110.3%
8 Jun 2026 → 15 Oct 2026
Ran from $3.10 to $6.52 — its strongest sustained advance this year.

Price outlook — trend & volatility model

● Trend: Below long-term trend
Price sits below its 200-day average, but the shorter-term averages are not cleanly aligned above/below it.
HorizonBear case (−1σ)Base caseBull case (+1σ)
1 Month$5.02 (-23.0%)$6.52$8.47 (+30.0%)
3 Months$4.14 (-36.5%)$6.52$10.26 (+57.4%)
6 Months$3.43 (-47.4%)$6.52$12.39 (+90.0%)
12 Months$2.63 (-59.7%)$6.52$16.16 (+147.8%)
Statistical, not machine-learning: a random-walk (no assumed drift) volatility model built from this ticker's own realized price history, plus a purely descriptive moving-average trend read. Illustrative only — not a price target and not financial advice. The bear and bull cases sit one standard deviation (1σ) below and above today's price, a range that covers about 68% of the outcomes the model treats as plausible, not a 68% chance of either case. Annualized volatility used: 90.8%, blended from this ticker's own 3-month and 1-year realized price history. Base case is deliberately flat — this quantifies a possible range, not a directional prediction. See the full model, including wider (≈95%) bands →

Comparable companies

Recent headlines

Recent insider activity

Sold 6,293 shares at $5.88 — Morris Milton Mayo, Director · 2026-09-08
Acquired 30,000 shares at $4.70 — Kurdikar Devdatt, President and CEO · 2026-08-13
Acquired 20,000 shares at $4.67 — Elguicze Jacob, SVP and CFO · 2026-08-13
Acquired 20,000 shares at $4.99 — Mann Jeffrey Z, Pres, Pharm Svc&Prod Mgmt, CLO · 2026-08-13
Acquired 45,000 shares at $4.97 — HOMBACH ROBERT J., Director · 2026-08-13
Source: SEC Form 4 filings. An "acquired" entry with no price is typically a stock award or option exercise rather than an open-market purchase. Search all insider trades →

Learn the basics

Prices and company data are delayed reference figures from public sources (Yahoo Finance, SEC EDGAR) and may be inaccurate or out of date. This page is informational only — it is not investment advice or a recommendation to buy or sell any security. Past performance does not indicate future results.